临床微生物学档案

  • 国际标准期刊号: 1989-8436
  • 期刊 h 指数: 22
  • 期刊引用分数: 7.55
  • 期刊影响因子: 6.38
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 全球影响因子 (GIF)
  • 开放档案倡议
  • 中国知网(CNKI)
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • Scimago期刊排名
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Evaluation of Dexamethasone and Remdesivir as Potential Anti-Viral Drugs Over others for the Treatment of the COVID-19 Patients

Rashed Noor, Yusra Binte Sikandar and Syed Abdullah Ibn Asaduzzaman

Lots of research based on drug designing as well as in silico study, cell culture/animal model study, and the clinical trials are being conducted perceive the suitable therapeutic drugs and to develop vaccines in order to alleviate the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although there are still no vaccines, some potential anti-viral drugs have been discovered of which remdesivir has been so far mostly accepted for the treatment purpose because of its multi-target actions. In addition to remdesivir, dexamethasone has been noticed with the capacity to protect the severely affected COVID-19 patients from death to some extent. Current review thus emphasized on both remdesivir and dexamethasone as the successful remedies for the ongoing pandemic; and projected on the possible mode of action of dexamethasone.